In today's health matters, two doses of the Human Papillomavirus (HPV) Vaccine may offer just as much protection against cervical cancer as the three dose regimen currently used.
These findings stem from an analysis of data from the national cancer institute's Costa Rica vaccine trial. More than 7000 women were enrolled in that study.
They were given either the HPV vaccine Cervarix or a Hepatitis A vaccine.
While researchers intended to give the women receiving Cervarix the full three doses, 20 percent got only one or two doses for a variety of reasons.
After four years the team found those who had two doses of Cervarix had the same level of protection against HPV infection as those who received all three doses.
Researchers say more studies are needed to evaluate the long-term effectiveness of fewer doses.
Their findings appear in the 'Journal of the National Cancer Institute.'